Enzymes that Unlock
Your Next Discovery
0

The ArcticZymes Leadership Team

Our leadership team is committed to creating a culture where exceptional scientific work thrives, paving the way for innovative solutions that  accelerate your progress with reliable, precision-engineered enzymes.

Michael B. Akoh
CEO
Bio
Børge Sørvoll
CFO
Bio
Dr. Marit Sjo Lorentzen
VP Operations
Bio
Dr. Olav Lanes
VP R&D and Applications
Bio
Dirk Hahneiser
VP Business Development & Marketing
Bio
Grethe Ytterstad
VP Regulatory Affairs
Bio
Dr. Jeremy Gillespie
VP Corporate Development
Bio

The board of directors

Dr. Marie Ann Roskrow
Chairman
Bio
Jane Theaker
Director
Bio
Edgar Koster
Director
Bio
Lill-Hege Henriksen
Observer - employee elected
Bio
Dr. Bernd Striberny
Director - employee elected
Bio

The ArcticZymes Leadership Team

Our leadership team is deeplycommitted to creating a culture where exceptional scientific work thrives,paving the way for the innovative solutions that to elevate our partnersproducts from good to great.

Børge Sørvoll
CFO
Børge Sørvoll
CFO

Børge Sørvoll (born 1975) assumed the position as CFO on Oct 1, 2014. He has previous experience from the position as SCM Manager at Subsea 7, and before that as CFO in Front Exploration and as Managing Director of Troms Kraft Invest. Børge holds a "Siviløkonom" degree in Finance from the University of Wyoming. Number of shares in ArcticZymes Technologies held by Mr. Sørvoll: 95,428. Number of options in ArcticZymes Technologies held by Mr. Sørvoll: 180,000

Grethe Ytterstad
VP Regulatory Affairs
Grethe Ytterstad
VP Regulatory Affairs

Grethe Ytterstad (born 1973) holds a Cand. Scient degree in Biology from The Arctic University of Norway. She rejoined ArcticZymes in June 2021 as QA and Regulatory Manager, and as of July 1st, 2023, she has taken on the role of VP Regulatory Affairs. Prior to her return to ArcticZymes, Grethe held the position of QA Manager at the Diagnostic Laboratory "Laboratoriemedisin" within the University Hospital of North Norway (UNN). She initially joined ArcticZymes (Biotec Pharmacon) in 2002, as a Process Engineer, where she later transitioned into QA. Her extensive knowledge in QA Management within the Diagnostics and Pharma sectors are reflected in her broad regulatory experience. She is well-versed in various regulations and standards, including GMP, MDR, IVDR, Blood and Cell Regulation, ISO 13485, ISO 14971, ISO 15189, ISO 9001, and ISO 17025. Number of shares in ArcticZymes Technologies held by Mrs. Ytterstad: 7.269. Number of options in ArcticZymes Technologies held by Mrs. Ytterstad: 0

Dirk Hahneiser
VP Business Development & Marketing
Dirk Hahneiser
VP Business Development & Marketing

Dirk Hahneiser (born 1968) joined ArcticZymes in 2022 as VP of Business Development and Marketing. He brings with him a wealth of commercial and marketing experience from Johnson & Johnson, Ecolab and Thermo Fisher Scientific. Prior to joining ArcticZymes, Dirk was the Head of Sales for the OEM Laboratory Products Business at Thermo Fisher Scientific, Director of Commercial Operations and Key Accounts at Ecolab and Business Unit Director at Johnson & Johnson. He holds a Master's of International Business and a B.S. Degree in Management from the Darla Moore School of Business at the University of South Carolina. Number of shares in ArcticZymes Technologies held by Mr. Hahneiser: 150. Number of options in ArcticZymes Technologies held by Mr. Hahneiser: 0.

Dr. Jeremy Gillespie
VP Corporate Development
Dr. Jeremy Gillespie
VP Corporate Development

Dr. Jeremy Gillespie joined ArcticZymes as VP Corporate Development in June 2023. With a Ph.D. in Biology and Biochemistry from the University of Bath, UK, Jeremy has extensive experience in commercial leadership roles with biotech companies including Invitrogen, ThermoFisher Scientific, Enzymatics (QIAGEN), and Kerry Foods. His expertise and vision are valuable assets to drive ArcticZymes' growth and success. Number of shares in ArcticZymes Technologies held by Dr. Gillespie: 0. Number of options in ArcticZymes Technologies held by Dr. Gillespie: 0.

Dr. Marit Sjo Lorentzen
VP Operations
Dr. Marit Sjo Lorentzen
VP Operations

Dr Lorentzen (born 1968) was granted a Dr Scient degree in Biotechnology from University of Tromsø in 2005. She joined the company (Biotec Pharmacon) as a Sr. Research Scientist in 2011 and holds the position as Director of Operations since 2020. She has extensive work experience within laboratory operations, management and research. She is employee elected to The Board of Directors in ArcticZymes Technologies. Number of shares in ArcticZymes Technologies held by Dr Lorentzen: 20,331. Number of options in ArcticZymes Technologies held by Dr Lorentzen: 115,000.

Dr. Olav Lanes
VP R&D and Applications
Dr. Olav Lanes
VP R&D and Applications

Dr Lanes (born 1972) was granted a Dr Scient degree in molecular biology from University of Tromsø in 2000. He joined the company (Biotec Pharmacon) as a researcher the same year and the position as Director of R&D and Applications since in 2016. Olav has extensive experience in innovation management and product development. Dr. Lanes is inventor and co-inventor of eight patent- or pending patent families, all today part of the IPR assets in the company. Number of shares in ArcticZymes Technologies held by Dr Lanes: 2000. Number of options in ArcticZymes Technologies held by Dr Lanes: 100,000.

Michael B. Akoh
CEO
Michael B. Akoh
CEO

Michael Benjamin Akoh (born 1973) joined ArcticZymes as CEO on September 18th, 2023. He has more than 20 years of global experience from the Life Science industry within the IVD, Medical Devices and CRO segments. Michael B. Akoh has had senior roles in both larger cooperations as well as in start-up and scale-up organisations. Most recently he was CCO at Pre Diagnostics and before that he was active as Managing Director of Wieslab AB, where he successfully scaled and grew the existing business as well as led the establishment of a new pharma services business area. Earlier on in his career he worked with commercialization of several successful solutions at Dako (Agilent) and Oticon (Demant). Mr. Akoh has a M.Sc. from Copenhagen Business School (CBS) in International Management and Marketing. Number of shares in ArcticZymes Technologies held by Mr. Akoh: 0. Number of options in ArcticZymes Technologies held by Mr. Akoh: 200,000